Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study-Reference-Cited by-同舟云学术

Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study

Published:2016-02-15 Issue:5 Volume:23 Page:404-411
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Sun Yinghao¹,Zou Qing²,Sun Zhongquan³,Li Changling⁴,Du Chuanjun⁵,Chen Zhiwen⁶,Shan Yuxi⁷,Huang Yiran⁸,Jin Jie⁹,Ye Zhang Qun¹⁰,Xie Liping¹¹,Lin Guowen¹²,Feng Yi¹³,De Porre Peter¹⁴,Liu Weiping¹³,Ye Dingwei¹²

Affiliation:

1. Department of Urology; Shanghai Changhai Hospital; Second Military Medical University; Shanghai China

2. Department of Oncology; Jiangsu Cancer Hospital; Nanjing China

3. Department of Urology; Huadong Hospital; Fudan University; Shanghai China

4. Department of Urology; Cancer Institute (Hospital); Peking Union Medical College and Chinese Academy of Medical Sciences; Beijing China

5. Department of Urology; Second Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou China

6. Urology Center; Southwest Hospital; Third Military Medical University; Chongqing China

7. Department of Urinary Surgery; Second Affiliated Hospital of Soochow University; Suzhou China

8. Department of Urology; School of Medicine; Renji Hospital; Shanghai Jiao Tong University; Shanghai China

9. Department of Urology; Peking University First Hospital and Institute of Urology; Peking University, National Urological Cancer; Beijing China

10. Department of Urology; Tongji Medical College; Tongji Hospital; Huazhong University of Science and Technology; Wuhan China

11. Department of Urology; School of Medicine; First Affiliated Hospital; Zhejiang University; Hangzhou China

12. Department of Urology; Fudan University Shanghai Cancer Center; Shanghai China

13. Janssen Research & Development; Beijing China

14. Janssen Research & Development; Beerse Belgium

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.13051/fullpdf

Reference28 articles.

1. International variation in prostate cancer incidence and mortality rates;Center;Eur. Urol.,2012

2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int. J. Cancer,2010

3. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study);Matsubara;Jpn. J. Clin. Oncol.,2014

4. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy;Satoh;Jpn. J. Clin. Oncol.,2014

5. International Agency for Research on Cancer Prostate cancer estimated incidence, mortality and prevalence worldwide in 2012 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

2. Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis;Prostate International;2024-08

3. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer;JAMA Oncology;2024-07-01

4. Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials;Clinical Genitourinary Cancer;2024-06

5. A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?;Critical Reviews in Oncology/Hematology;2024-04